Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03203369 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN
A Phase 1 study, sponsored by Cellectis S.A..
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT03203369: Clinical Trial Phase 1 study, sponsored by Cellectis S.A..
NCT03203369 is a Phase 1 study that was terminated before completion, run by Cellectis S.A.. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03203369, a Phase 1 study, was terminated before completion, sponsored by Cellectis S.A..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
A Phase 1 dose-finding study of Universal Chimeric Antigen Receptor T-cells targeting cluster of differentiation (CD) 123 (UCART123) administered intravenously to patients with relapsed or refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), followed by a dose expansion phase in relapsed or refractory BPDCN patients or newly diagnosed BPDCN patients.
Interventions
- BIOLOGICAL UCART123
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-06-28 |
| Est. Completion | 2019-06-27 |
| Phase | Phase 1 |
Why NCT03203369 stopped before completion
NCT03203369 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which UCART123 is the first listed.
NCT03203369 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03203369 about?
NCT03203369 is a clinical study titled "Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN". A Phase 1 dose-finding study of Universal Chimeric Antigen Receptor T-cells targeting cluster of differentiation (CD) 123 (UCART123) administered intravenously to patients with relapsed or refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), followed by a dose expansion phase in relapsed...
What is the current status of trial NCT03203369?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2017-06-28. Estimated completion is 2019-06-27.
What interventions are being tested in trial NCT03203369?
The interventions under investigation include: UCART123 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03203369?
This trial is sponsored by Cellectis S.A., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03203369's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI